EUVIMEDEUVIMED entdecken
Open Access

Estimated US Cancer Deaths Prevented With Increased Use of Lung, Colorectal, Breast, and Cervical Cancer Screening

Amy B Knudsen, Amy Trentham-Dietz, Jane J Kim, Jeanne S Mandelblatt, Rafael Meza, Ann G Zauber, Philip E Castle, Eric J Feuer

JAMA Network Open · 22.11.2023 · 6 (11) · e2344698

DOI: 10.1001/jamanetworkopen.2023.44698 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 22.11.2023. Verfasst von Amy B Knudsen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Technology Assessment, Massachusetts General Hospital, Boston. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Increased use of recommended screening could help achieve the Cancer Moonshot goal of reducing US cancer deaths.

Objective

To estimate the number of cancer deaths that could be prevented with a 10–percentage point increase in the use of US Preventive Services Task Force (USPSTF)-recommended screening. Design, Setting, and Participants This decision analytical model study is an extension of previous studies conducted for the USPSTF from 2018 to 2023. This study simulated contemporary cohorts of US adults eligible for lung, colorectal, breast, and cervical cancer screening. Exposures Annual low-dose computed lung tomography among eligible adults aged 50 to 80 years; colonoscopy every 10 years among adults aged 45 to 75 years; biennial mammography among female adults aged 40 to 74 years; and triennial cervical cytology screening among female adults aged 21 to 29 years, followed by human papillomavirus testing every 5 years from ages 30 to 65 years. Main Outcomes and Measures Estimated number of cancer deaths prevented with a 10–percentage point increase in screening use, assuming screening commences at the USPSTF-recommended starting age and continues throughout the lifetime. Outcomes were presented 2 ways: (1) per 100 000 and (2) among US adults in 2021; and they were expressed among the target population at the age of screening initiation. For lung cancer, estimates were among those who will also meet the smoking eligibility criteria during their lifetime. Harms from increased uptake were also reported.

Results

A 10–percentage point increase in screening use at the age that USPSTF recommended screening commences was estimated to prevent 226 lung cancer deaths (range across models within the cancer site, 133-332 deaths), 283 (range, 263-313) colorectal cancer deaths, 82 (range, 61-106) breast cancer deaths, and 81 (1 model; no range available) cervical cancer deaths over the lifetimes of 100 000 persons eligible for screening. These rates corresponded with an estimated 1010 (range, 590-1480) lung cancer deaths prevented, 11 070 (range, 10 280-12 250) colorectal cancer deaths prevented, 1790 (range, 1330-2310) breast cancer deaths prevented, and 1710 (no range available) cervical cancer deaths prevented over the lifetimes of eligible US residents at the recommended age to initiate screening in 2021. Increased uptake was also estimated to generate harms, including 100 000 (range, 45 000-159 000) false-positive lung scans, 6000 (range, 6000-7000) colonoscopy complications, 300 000 (range, 295 000-302 000) false-positive mammograms, and 348 000 (no range available) colposcopies over the lifetime. Conclusions and Relevance In this decision analytical model study, a 10–percentage point increase in uptake of USPSTF-recommended lung, colorectal, breast, and cervical cancer screening at the recommended starting age was estimated to yield important reductions in cancer deaths. Achieving these reductions is predicated on ensuring equitable access to screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsBreast NeoplasmsLung NeoplasmsColorectal NeoplasmsAdultHumansFemaleEarly Detection of CancerMass ScreeningLung

Autor:innen und Institutionen

  • Institute for Technology Assessment, Massachusetts General Hospital, Boston.
  • Department of Radiology, Harvard Medical School, Boston, Massachusetts.
  • Department of Population Health Sciences and Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison.
  • Department of Health Policy and Management, Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.
  • Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia.

Förderung

  • NCI NIH HHS

Zitieren

APA

Knudsen, A. B., Trentham-Dietz, A., Kim, J. J., Mandelblatt, J. S., Meza, R., Zauber, A. G., Castle, P. E., & Feuer, E. J. (2023). Estimated US Cancer Deaths Prevented With Increased Use of Lung, Colorectal, Breast, and Cervical Cancer Screening. JAMA Network Open, 6(11), e2344698. https://doi.org/10.1001/jamanetworkopen.2023.44698

Vancouver

Knudsen AB, Trentham-Dietz A, Kim JJ, Mandelblatt JS, Meza R, Zauber AG, et al. Estimated US Cancer Deaths Prevented With Increased Use of Lung, Colorectal, Breast, and Cervical Cancer Screening. JAMA Network Open. 2023;6(11):e2344698. doi:10.1001/jamanetworkopen.2023.44698

BibTeX
@article{Knudsen2023,
  author = {Knudsen, Amy B and Trentham-Dietz, Amy and Kim, Jane J and Mandelblatt, Jeanne S and Meza, Rafael and Zauber, Ann G and Castle, Philip E and Feuer, Eric J},
  title = {Estimated US Cancer Deaths Prevented With Increased Use of Lung, Colorectal, Breast, and Cervical Cancer Screening},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {11},
  pages = {e2344698},
  doi = {10.1001/jamanetworkopen.2023.44698}
}
Kostenlos starten →